Denosumab Triggers Paradoxical Hungry Bone Syndrome-Like State in Multiple Myeloma Patient

Published on July 6, 2026

A recent study from JCEM Case Reports reveals that denosumab, a human monoclonal antibody widely used to prevent fractures, can cause a rare “hungry bone syndrome-like state” even in purely bone-destroying (osteolytic) cancers such as multiple myeloma.

The post Denosumab Triggers Paradoxical Hungry Bone Syndrome-Like State in Multiple Myeloma Patient appeared first on Endocrine News.

Continue reading on website
Other news

Looking Back: Unforgettable Moments from ENDOs Past

July 2, 2026
Since ENDO 2026 in Chicago is fresh in our minds, Endocrine News quizzed Endocrine Society members to see what their favorite memories of past ENDOs have been. From professional connections to new job leads, lifelong friendships, and even some unforgettable meals, ENDO is the only place to be for the international endocrinology community. Every year, […]The post Looking Back: Unforgettable Moments

Growth Therapies Fall Short for Girls with Classical CAH

July 7, 2026
Growth-promoting therapies frequently prescribed to counteract the adult height loss associated with classical congenital adrenal hyperplasia (CAH) may provide greater height benefits in boys, according to a large multicenter study recently published in The Journal of Clinical Endocrinology & Metabolism. The findings reveal a gender-dependent difference in how effectively these commonly deployed h